is an enzyme that cleaves a set of transmembrane proteins, including BCMA.
Kitamoto, "Novel [alpha]- secretase
cleavage of Alzheimer's amyloid [beta] precursor protein in the endoplasmic reticulum of COS7 cells," Neuroscience Letters, vol.
For instance, inhibition of [beta]- and [gamma]-secretases
will interfere with proteolytic processing of other secretase
substrates such as sialyltransferase (35) and Notch, (33,36) respectively, possibly resulting in perturbation of the immune system.
The company intends to file an IND on the lead modulator of gamma- secretase
The company announced semagacestat, a gamma secretase
inhibitor, endured two on-going long-term studies, during which the drug not only failed at slowing Alzheimer's progression, but also affected the ability to perform activities of daily living.
(GS) is a membrane-embedded multi-protein enzyme composed of presenilin/nicastrin/Aph 1 and Pen 2 .
The pill semagacestat inhibits an enzyme called gamma secretase
thatAAEs tied to amyloid production.
Working with laboratory mice, the researchers tested whether the drug DAPT--one of a class of drugs called gamma secretase
inhibitors that is being studied as a treatment for AD--could reduce damage associated with TBI.
There is compelling evidence that sAPPbeta, the ectodomain of amyloid precursor protein (APP) shed through beta secretase
cleavage, is an important component in the pathogenesis of AD," said Joe Bertelsen, neuroscience product manager, Covance.
The findings, published in the journal Nature, show drugs called gamma secretase
modulators work to stop the build-up of a protein thought to trigger Alzheimer's.
The problem with most proposed methods of blocking beta secretase
, the study found, is that they are designed to work outside of the affected brain cells.
Other research has shown that statins (cholesterol-lowering drugs) and estrogen activate a form of secretase
that destroys A[beta], says Gandy.
Miele's study shows that inhibiting gamma secretase
can block intercellular communications in cancer cells as well.
Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics of Gamma Secretase
Eisai Co Ltd, a Japan-based pharmaceutical company, announced yesterday that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase
cleaving enzyme (BACE) inhibitor elenbecestat in patients with early Alzheimer's disease (AD).